Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc.'s chief financial officer reported equity compensation activity involving restricted stock units and related tax withholding. On 12/15/2025, 199 shares of common stock were acquired in connection with restricted stock units, and 199 shares were then withheld to satisfy FICA and associated income tax obligations on a 2025 restricted stock unit grant, using a share price of $350.32.
After these transactions, the officer directly held 134,941.3479 shares of common stock and 4,534 restricted stock units. The restricted stock units referenced in the filing vest in three equal installments on 11/12/2026, 11/12/2027 and 11/12/2028.
Cencora, Inc. senior vice president and chief accounting officer Lazarus Krikorian reported insider equity activity dated 12/15/2025. A grant of 91 restricted stock units converted into the same number of common shares, and an equal 91-share amount was withheld to cover FICA and related income taxes, using the closing stock price of $350.32 on that date. After these transactions, Krikorian beneficially owned 21,185 shares of Cencora common stock directly, along with 2,180 restricted stock units. The restricted stock units referenced in the footnotes vest in three equal installments on 11/12/2026, 11/12/2027, and 11/12/2028.
A holder of COR common stock has filed a Rule 144 notice to sell 4031 shares on the NYSE, with an aggregate market value of $1383580.29, out of 193993444 shares of this class outstanding.
The shares were acquired through restricted stock vesting from the issuer as compensation on four dates in 2025, in amounts of 1375, 1032, 1022, and 602 shares, with payment recorded on the same dates. The planned sale date is approximately December 17, 2025, through Fidelity Brokerage Services LLC. The person signing the notice represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Cencora, Inc. plans to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology from TPG and other shareholders. OneOncology is described as a physician-led national platform supporting independent oncology-focused medical specialty practices. Cencora will pay approximately $3.6 billion for these equity interests and retire $1.3 billion of OneOncology’s existing corporate debt, for total cash consideration of about $5.0 billion.
The company expects to fund the transaction with new debt financing and has obtained $4.5 billion in bridge financing commitments. OneOncology’s affiliated practices and management will retain a minority ownership interest, and completion of the deal is subject to customary closing conditions, including receipt of required regulatory approvals.
Cencora, Inc. is a large global pharmaceutical sourcing and distribution company serving healthcare providers and drug manufacturers across human and animal health. It distributes branded, specialty, and generic drugs and provides services such as data analytics, reimbursement support, logistics, pharmacy management, and packaging.
In fiscal 2025, the company continued to execute a strategy focused on its core U.S. and international distribution businesses while expanding higher-margin manufacturer services. Cencora acquired an 85% stake in Retina Consultants of America for $4,042.0 million in cash plus contingent consideration tied to equity units and future business objectives, and it previously invested $718.4 million for a 34.9% interest in oncology joint venture OneOncology.
Customer concentration is significant: Walgreens and Boots generated about 25% of revenue and roughly 38% of accounts receivable, while Evernorth Health Services contributed about 13% of revenue. The top 10 customers represented approximately 66% of revenue. Cencora is reorganizing its reporting into U.S. Healthcare Solutions, International Healthcare Solutions, and Other, and highlights extensive regulatory, litigation, cybersecurity, and geopolitical risks. The company reports more than 51,000 employees worldwide and emphasizes talent development, safety, and broad benefit programs.
Cencora, Inc. (COR) President & CEO reports RSU activity. Director and executive Robert P. Mauch reported the vesting and conversion of 5,790 restricted stock units into common stock on 11/20/2025. These restricted stock units were granted for no cash consideration and are scheduled to vest in three equal installments on 11/20/2025, 11/20/2026 and 11/20/2027.
To cover tax withholding related to the vesting, 2,144 shares of common stock were disposed of at a price of $362.07 per share. After these transactions, Mauch beneficially owns 69,392 shares of Cencora common stock directly.
Cencora, Inc. (COR) Chief Financial Officer James F. Cleary reported equity compensation activity involving restricted stock units and common stock. On 11/20/2025, 1,876 restricted stock units with a conversion price of $0 were exercised into the same number of shares of common stock, increasing his directly held stake.
On the same date, 824 shares of common stock were disposed of at $362.07 per share to cover tax withholding tied to the vesting of these restricted stock units. After these transactions, Cleary directly owned 134,941.3479 shares of Cencora common stock. The restricted stock units were originally granted for no cash consideration and vest in three equal installments on 11/20/2025, 11/20/2026, and 11/20/2027.
Cencora, Inc. (COR) Executive Vice President Elizabeth S. Campbell reported equity activity on a Form 4. On 11/20/2025, 1,590 restricted stock units were converted into the same number of shares of common stock, received for no cash consideration as part of prior equity awards.
To cover taxes on this vesting, 736 shares of common stock were withheld at a price of $362.07 per share. After these transactions, Campbell directly beneficially owned 27,242.141 shares of Cencora common stock.
Cencora, Inc. (COR) filed a Form 4 reporting equity activity by its SVP & Chief Accounting Officer, Lazarus Krikorian. On 11/20/2025, 1,023 shares of common stock were acquired through the vesting and settlement of previously granted restricted stock units. On the same date, 421 shares were disposed of at a price of $362.07 per share to cover tax withholding obligations.
After these transactions, Krikorian directly beneficially owned 21,185 shares of Cencora common stock and held 2,262 restricted stock units, which were originally granted for no cash consideration and vest in three equal installments on 11/20/2025, 11/20/2026, and 11/20/2027.
Cencora, Inc. executive Pawan Verma reported routine equity transactions on Form 4. On 11/20/2025, 1,974 restricted stock units were converted into shares of common stock, reflecting the vesting of a prior equity grant received for no consideration.
On the same date, 1,010 shares were withheld at a price of $362.07 to cover tax obligations tied to the vesting. After these transactions, Verma directly beneficially owned 5,148.05 shares of Cencora common stock and 3,948 restricted stock units remained outstanding.